LEO Pharma to acquire Astellas' global dermatology portfolio

11 November 2015

Danish privately-held LEO Pharma has entered into an asset purchase agreement under which Japanese drug major Astellas Pharma (TYO: 4503) will transfer its global dermatology business to LEO Pharma for 675 million euros ($725 million).

Under the terms of the accord, the assets and associated responsibilities relating to Astellas' global portfolio of dermatology products - which include Protopic (tacrolimus) ointment, treatment for eczema, and other products for the treatment of acne and skin infection - will be transferred to LEO Pharma (except for Protopic in Japan).

The transaction is subject to the satisfaction of customary closing conditions, including review and approval by competition authorities, and is anticipated to close in the first quarter of 2016. The addition of Astellas' dermatology products will extend LEO Pharma's reach to millions more people living with skin diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK